Efficacy and safety of endoscopic retrograde cholangiopancreatography in the treatment of bile duct stones

Figure 1 Changes in total bilirubin and amylase levels before and after treatment. A: Total bilirubin levels pre- and post-treatment; B: Amylase levels pre- and post-treatment. TBil: Total bilirubin; AMS: Amylase; CBDE: Common bile duct exploration; ERCP: Endoscopic retrograde cholangiopancreatography. ^cP < 0.001 vs pretreatment values, ^bP < 0.01 vs pretreatment values.

Figure 2 Surgery-related indicators in two groups. A: Stone removal time; B: Operation time; C: Intraoperative blood loss; D: Hospitalization time. CBDE: Common bile duct exploration; ERCP: Endoscopic retrograde cholangiopancreatography. ^cP < 0.001 vs common bile duct exploration group, ^bP < 0.01 vs common bile duct exploration group.

Figure 3 Postoperative recovery in two groups. A: Intestinal recovery time; B: Time to jaundice resolution; C: Time to biliary drainage removal; D: Time to postoperative activity recovery. CBDE: Common bile duct exploration; ERCP: Endoscopic retrograde cholangiopancreatography. ^cP < 0.001 vs common bile duct exploration group, ^bP < 0.01 vs common bile duct exploration group.